User profiles for Andrea Kreidenweiss
 | Andrea KreidenweissUniversitätsklinikum Tübingen Verified email at uni-tuebingen.de Cited by 1585 |
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded …
…, E Koehne, A Kreidenweiss… - The Lancet Infectious …, 2022 - thelancet.com
Background Additional safe and efficacious vaccines are needed to control the COVID-19
pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA …
pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA …
[HTML][HTML] Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
…, K Althaus, R Fendel, A Kreidenweiss… - Nature …, 2021 - nature.com
SARS-CoV-2 is evolving with mutations in the receptor binding domain (RBD) being of
particular concern. It is important to know how much cross-protection is offered between strains …
particular concern. It is important to know how much cross-protection is offered between strains …
[HTML][HTML] Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial
…, JJ Bosch, R Fendel, A Kreidenweiss… - Wiener Klinische …, 2021 - Springer
Background We used the RNActive® technology platform (CureVac NV, Tübingen, Germany)
to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding …
to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding …
Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers
…, P Mann, J Bosch, R Fendel, JJ Gabor, A Kreidenweiss… - MedRxiv, 2020 - medrxiv.org
There is an urgent need for vaccines to counter the COVID-19 pandemic due to infections
with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from …
with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from …
[HTML][HTML] Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon
Background The emergence and spread of Plasmodium falciparum resistance to almost all
available antimalarial drugs necessitates the search for new chemotherapeutic compounds. …
available antimalarial drugs necessitates the search for new chemotherapeutic compounds. …
[HTML][HTML] A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection
…, J Ibáñez, J Flügge, R Fendel, A Kreidenweiss… - npj Vaccines, 2022 - nature.com
Immunization with radiation-attenuated Plasmodium falciparum (Pf) sporozoites (SPZ) in
PfSPZ Vaccine, has provided better vaccine efficacy (VE) against controlled human malaria …
PfSPZ Vaccine, has provided better vaccine efficacy (VE) against controlled human malaria …
[HTML][HTML] Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial
…, M Rodi, D Egger-Adam, A Kreidenweiss… - Nature …, 2021 - nature.com
Immunization with Plasmodium falciparum (Pf) sporozoites under chemoprophylaxis (PfSPZ-CVac)
is the most efficacious approach to malaria vaccination. Implementation is hampered …
is the most efficacious approach to malaria vaccination. Implementation is hampered …
Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data
AB Hounkpatin, A Kreidenweiss… - Infection and drug …, 2019 - Taylor & Francis
Tafenoquine is an 8-aminoquinoline with activity against all human life cycle stages of
Plasmodium vivax, including dormant liver stages – so called hypnozoites. Its long half-life of ~15 …
Plasmodium vivax, including dormant liver stages – so called hypnozoites. Its long half-life of ~15 …
[HTML][HTML] Longitudinal monitoring of lactate in hospitalized and ambulatory COVID-19 patients
TP Velavan, A Kreidenweiss, J Gabor… - The American Journal …, 2021 - ncbi.nlm.nih.gov
Hypoxemia is readily detectable by assessing SpO 2 levels, and these are important in
optimizing COVID-19 patient management. Hyperlactatemia is a marker of tissue hypoxia, …
optimizing COVID-19 patient management. Hyperlactatemia is a marker of tissue hypoxia, …
[HTML][HTML] First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine …
…, S Justesen, PK Khalifé, A Kreidenweiss… - The Lancet …, 2023 - thelancet.com
Background Capsid virus-like particles (cVLP) have proven safe and immunogenic and can
be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …